See the DrugPatentWatch profile for Prolia
Prolia, also known by its generic name denosumab, is an injectable medication used to treat specific bone conditions. It works by inhibiting osteoclast activity, which are cells responsible for bone resorption. This action helps to increase bone mineral density and reduce the risk of fractures [1].
What conditions does Prolia treat?
Prolia is prescribed for several conditions:
* Osteoporosis in postmenopausal women: It is used to reduce the risk of fractures, including in the spine and hip [1].
* Osteoporosis in men at high risk for fracture: Similar to its use in women, it helps lower fracture risk [1].
* Glucocorticoid-induced osteoporosis: This refers to bone loss caused by long-term use of corticosteroid medications [1].
* Bone loss in men receiving androgen deprivation therapy for prostate cancer: These treatments can lead to decreased bone density [1].
* Treatment of giant cell tumor of bone in adults and adolescents 12 years and older who are skeletally mature: This is a rare bone tumor [1].
How is Prolia administered?
Prolia is given as a subcutaneous injection, meaning it is injected under the skin. The standard dose for osteoporosis is 60 mg every six months [1]. For giant cell tumor of bone, the dose is 120 mg every four weeks [1]. It is typically administered by a healthcare professional [1].
What are the potential side effects of Prolia?
Common side effects of Prolia can include pain in the extremities, muscle pain, joint pain, and back pain [1]. More serious, though less common, side effects can include serious infections, low calcium levels (hypocalcemia), osteonecrosis of the jaw (ONJ), and severe skin reactions [1]. Some patients may also experience atypical femur fractures [1].
How long does Prolia treatment typically last?
The duration of Prolia treatment depends on the condition being treated and the patient's response. For osteoporosis, treatment is often long-term, with decisions about continuing or stopping therapy based on fracture risk. For giant cell tumor of bone, treatment continues as long as it is effective and tolerated [1].
Can Prolia be used by everyone?
Prolia is not suitable for everyone. It is contraindicated in patients with hypocalcemia. Before starting Prolia, healthcare providers assess patients for risk factors and ensure calcium and vitamin D levels are adequate [1]. Pregnant or breastfeeding individuals should also discuss its use with their doctor [1].
What is the mechanism of action for Prolia?
Prolia contains denosumab, a fully human monoclonal antibody. It targets and binds to receptor activator of nuclear factor kappa-B ligand (RANKL), a protein essential for the formation, function, and survival of osteoclasts. By inhibiting RANKL, denosumab reduces osteoclast activity, thereby decreasing bone resorption and increasing bone mass and strength [1].
What is the patent status for Prolia?
Information regarding drug patents, including those for Prolia, can be found on resources like DrugPatentWatch.com [2]. Drug patents grant exclusivity for a period, preventing generic versions from entering the market. The expiration of these patents typically opens the door for biosimilar competition.
Who manufactures Prolia?
Prolia is manufactured by Amgen [3].